Szántó F, Hörömpöli C
Orv Hetil. 1996 Jun 16;137(24):1299-301.
The authors report on their observations with the treatment of premenstrual syndrome with gestogens of different dosage. The efficacy of medroxyprogeszteron-acetate therapy with 20 mg/die and 40 mg/die between the 15. and 26. days of menstruation were studied with the help of the premenstrual syndrome index. The connection between the efficacy and dosage of the efficacy and period of therapy were observed. According to the data the elevated dosage of medroxyprogeszteron-acetate does not increase the efficacy of therapy. After 3 month treatment period 67% of the complaints disappeared. Further therapy does not increase efficacy, but has been important to prevent remissions. According to the data of this study the authors opinion is that a dosage of 20 mg/die medroxyprogeszteron-acetate treatment between the 15. and 26. days of menstrual cycle is sufficient to treat premenstrual syndrome.
作者报告了他们使用不同剂量孕激素治疗经前综合征的观察结果。借助经前综合征指数,研究了在月经周期第15至26天使用20毫克/天和40毫克/天醋酸甲羟孕酮治疗的疗效。观察了疗效与剂量以及治疗周期之间的关系。根据数据,醋酸甲羟孕酮剂量增加并未提高治疗效果。经过3个月的治疗期,67%的症状消失。进一步治疗并未提高疗效,但对于预防复发很重要。根据本研究数据,作者认为在月经周期第15至26天使用20毫克/天醋酸甲羟孕酮治疗足以治疗经前综合征。